drugset / Trial / NCT05696613
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
Timeline
- Start
- 2023-03-13
- Primary completion
- 2027-04-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | 1 g | Intravenous |
| Subject | SNP-ACTH (1-39) | Unknown | 3 mg | Subcutaneous |
| Subject | SNP-ACTH (1-39) | Unknown | 5 mg | Subcutaneous |